Beta-blocker therapy is a pharmacological approach widely employed in cardiovascular medicine to manage various conditions. These medications, known as beta-blockers, function by blocking the effects of adrenaline, thus reducing heart rate and blood pressure. Beta blockers have proven efficacy in treating conditions such as hypertension, angina, and certain cardiac arrhythmias. They are also commonly prescribed for heart failure patients to improve cardiac function and reduce symptoms. Moreover, beta-blocker therapy plays a crucial role in post-myocardial infarction care, aiding in preventing secondary cardiovascular events. The versatility of beta blockers extends beyond cardiovascular applications, as they are sometimes used to alleviate symptoms associated with anxiety and migraine headaches. While well-tolerated by many patients, it is essential to consider individual medical histories and potential contraindications when prescribing beta-blocker therapy. As with any medical intervention, close collaboration between healthcare providers and patients ensures the optimal management of cardiovascular health
.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India